Maul Lara V, Weichenthal Michael, Kähler Katharina C, Hauschild Axel
Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
J Immunother. 2016 May;39(4):188-90. doi: 10.1097/CJI.0000000000000118.
Pembrolizumab, an anti-programmed death-1 monoclonal antibody, has been approved by the Food and Drug Administration in 2014 on the basis of improved progression-free and overall survival in metastatic melanoma. We report for the first time a successful treatment with a programmed death-1 antibody in a 69-year-old metastastic melanoma patient with a Churg-Strauss lung vasculitis and a prior ipilimumab-induced autoimmune colitis. This case report suggests that pembrolizumab can be given with caution to patients with underlying autoimmune disease. As the use of checkpoint inhibitors expands, knowledge about their safety in patients with underlying autoimmune diseases will become increasingly important, in particular because these patients are typically excluded from clinical trials with immune-checkpoint inhibitors.
帕博利珠单抗是一种抗程序性死亡-1单克隆抗体，于2014年获美国食品药品监督管理局批准，其依据是可改善转移性黑色素瘤患者的无进展生存期和总生存期。我们首次报告了一名69岁患有转移性黑色素瘤、Churg-Strauss肺血管炎且曾因使用伊匹单抗诱发自身免疫性结肠炎的患者，使用程序性死亡-1抗体治疗成功的案例。本病例报告表明，对于患有潜在自身免疫性疾病的患者，可谨慎使用帕博利珠单抗。随着检查点抑制剂的应用范围不断扩大，了解其在患有潜在自身免疫性疾病患者中的安全性将变得越来越重要，特别是因为这些患者通常被排除在免疫检查点抑制剂的临床试验之外。
